ClinicalTrials.gg
Sign In
RecruitingNCT06348459RiTEPUpdated Oct 6, 2026

Registry of Catheter Intervention in Pulmonary Embolism

An observational study in Pulmonary Embolism, Pulmonary Embolism Acute Massive and Pulmonary Embolism Acute, sponsored by Hospital San Carlos, Madrid. Recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Hospital San Carlos, Madrid · Observational

From the registry’s dates

  • Started Sep 2018; still recruiting 8 years 1 month later.
Updated Oct 6, 20261 site added1 site removedGo to Updates ↓
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
300
Ages
18 Years and older
Sex
All
01

Study summary

Multicenter longitudinal observational ambispective (retrospective cases from 2014 and prospective from 2018 onwards) cohort study. The registry recruits a series of consecutive patients admitted for moderate-high risk or high-risk pulmonary embolism (according to 2019 European Society of Cardiology guidelines) treated invasively. This study aims to describe the acute management of the safety and effectiveness of different percutaneous interventions for acute pulmonary embolism.

02

Conditions studied

  • Pulmonary Embolism
  • Pulmonary Embolism Acute Massive
  • Pulmonary Embolism Acute
  • Pulmonary Embolism and Thrombosis
  • Pulmonary Thromboembolisms

Keywords

  • Aspiration Thrombectomy
  • Percutaneous Aspiration Thrombectomy
  • Local Thrombolysis
03

In context

Pulmonary Embolism

832 studies on the registry are indexed under Pulmonary Embolism; 171 are open to participants now.

This study's planned enrollment of 300 is below the median of 361 across 366 observational studies indexed under Pulmonary Embolism.

Browse Pulmonary Embolism studies →

Lead sponsor

Hospital San Carlos, Madrid is the lead sponsor of 74 studies on the registry; 17 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Consecutive patients admitted for moderate-high risk or high-risk PE and treated invasively with any kind of catheter-directed intervention.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adult patients (aged 18 years old or older)
  • confirmed diagnosis of acute PE (on computed tomography or echocardiogram plus pulmonary angiography)
  • high-risk PE or intermediate-high risk according to ESC risk stratification in the 2019 guidelines (briefly, elevated cardiac biomarkers [troponin or N-terminal pro-B-type natriuretic peptide], and right ventricle to left ventricle ratio > 0.9 [on computed tomography or echocardiogram], and PE severity index III to IV or simplified PE severity index=1
  • eligibility for catheter-directed intervention

Exclusion criteria

Exclusion Criteria:

  • unconfirmed diagnosis of PE
  • undefined risk stratification, and
  • PE with uncertain chronology or beyond seven days of symptom initiation.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
300 participants (estimated)
Target follow-up
2 Years
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. All cause-death

    Time frame: during hospital admission (up to day 10)

Secondary outcomes

  1. all cause-death

    Time frame: 48 hours

  2. all cause-death

    Time frame: 30 days

  3. all cause-death

    Time frame: 2 year

  4. procedural success

    defined as technical procedure completed without procedural complications or 48-hour death

    Time frame: 48 hours

  5. in-hospital complications

    Time frame: during hospital admission (up to day 10)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Ramos-Lopez N, Ferrera C, Luque T, Enriquez-Vazquez D, Mahia-Casado P, Galvan-Herraez L, Pedrajas JM, Salinas P; working group. Impact of a pulmonary embolism response team initiative on hospital mortality of patients with bilateral pulmonary embolism. Med Clin (Barc). 2023 Jun 9;160(11):469-475. doi: 10.1016/j.medcli.2022.12.017. Epub 2023 Feb 16. English, Spanish. PubMed 36801109 ↗
  • Salinas P, Vazquez-Alvarez ME, Salvatella N, Ruiz Quevedo V, Velazquez Martin M, Valero E, Rumiz E, Jurado-Roman A, Lozano I, Gallardo F, Amat-Santos IJ, Lorenzo O, Portero Portaz JJ, Huanca M, Nombela-Franco L, Vaquerizo B, Ramallal Martinez R, Maneiro Melon NM, Sanchis J, Berenguer A, Gallardo-Lopez A, Gutierrez-Ibanes E, Mejia-Renteria H, Cordoba-Soriano JG, Jimenez-Mazuecos JM. Catheter-directed therapy for acute pulmonary embolism: results of a multicenter national registry. Rev Esp Cardiol (Engl Ed). 2024 Feb;77(2):138-147. doi: 10.1016/j.rec.2023.06.005. Epub 2023 Jun 22. English, Spanish. PubMed 37354942 ↗
09

Updates

1 registry update since Sep 25, 2026
Sites
1 site added, 1 site removed
Show site
  • Hospital Clinico San Carlos · Madrid, Spain
Show 1 removed
  • Hospital Clinico San Carlos · Madrid, Spain
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    1 site added, 1 site removed
    Show site
    • Hospital Clinico San Carlos · Madrid, Spain
    Show 1 removed
    • Hospital Clinico San Carlos · Madrid, Spain
    + 5 other changes: verification date, oversight details, references, data sharing statement and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06348459
Lead sponsor
Hospital San Carlos, Madrid
Collaborators
Asociación de Cardiología Intervencionista de la Sociedad Española de Cardiología
Responsible party
Pablo Salinas (MD, PhD, Hospital San Carlos, Madrid) — Principal investigator
First posted
Apr 4, 2024
Start date
Sep 18, 2018
Primary completion
Dec 31, 2029 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Oct 6, 2026

Study contacts

Pablo Salinas, MD, PhD
Contact
salinas.pablo@gmail.com
+34 913303000

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Pulmonary Embolism →

Other studies from this sponsor

Hospital San Carlos, Madrid

Start the discussion